Prevnar 13 Recommendation For Medicare Population May Be Short Lived
This article was originally published in The Pink Sheet Daily
Executive Summary
CDC advisory committee support for Pfizer pneumococcal vaccine in adults 65 and older comes with caveat that recommendation will be re-examined, and possibly revised, in 2018 due to effects of herd immunity.
You may also be interested in...
US CDC Panel’s Pneumococcal Vaccine Recommendations Leave Confusion In Their Wake
Advisory Committee on Immunization Practices’ October vote on use of Pfizer’s Prevnar 20 and Merck & Co’s Vaxneuvance was more restrictive than intended, inadvertently leaving out guidance for people who were previously vaccinated with Prevnar 13.
Prevnar 13 Loses ‘Routine’ Endorsement For Older Adults In CDC Panel Vote
ACIP still supports use of Pfizer’s pneumococcal vaccine in immunocompetent individuals ages 65 years and older based on shared clinical decision-making, but concludes that routine immunization is no longer warranted due to herd effect from pediatric vaccination.
Pfizer’s Prevnar 13 Is Approved For Older Children As Use In Adults Lags
FDA approved use of the pneumococcal vaccine in children and adolescents aged six to 17 years; uptake in adults 50 and older has been impacted by the delay in getting an ACIP vote on treatment, which is expected later this year.